Legend Biotech Corp LEGN
We take great care to ensure that the data presented and summarized in this overview for Legend Biotech Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LEGN
View all-
Price T Rowe Associates Inc Baltimore, MD11.5MShares$522 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.51MShares$341 Million5.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.64MShares$302 Million7.6% of portfolio
-
Black Rock Inc. New York, NY5.72MShares$260 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.77MShares$217 Million1.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.81MShares$128 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X02.36MShares$107 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA2.16MShares$98.3 Million0.02% of portfolio
-
Massachusetts Financial Services CO Boston, MA1.96MShares$89.1 Million0.03% of portfolio
-
Braidwell LP Stamford, CT1.67MShares$75.9 Million2.32% of portfolio
Latest Institutional Activity in LEGN
Top Purchases
Top Sells
About LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Insider Transactions at LEGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|